Tempus AI Inc. (TEM)
| Bid | 43.01 |
| Market Cap | 7.23B |
| Revenue (ttm) | 693.4M |
| Net Income (ttm) | -705.81M |
| EPS (ttm) | -6.23 |
| PE Ratio (ttm) | -6.91 |
| Forward PE | -94.46 |
| Analyst | Buy |
| Ask | 43.07 |
| Volume | 6,772,699 |
| Avg. Volume (20D) | 14,384,967 |
| Open | 43.67 |
| Previous Close | 42.12 |
| Day's Range | 41.98 - 44.77 |
| 52-Week Range | 22.89 - 91.45 |
| Beta | 7.76 |
About TEM
Tempus AI, Inc operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company also offers Insights, a license library of linked clinical, molecular, and imaging de-iden...
Analyst Forecast
According to 11 analyst ratings, the average rating for TEM stock is "Buy." The 12-month stock price forecast is $60, which is an increase of 39.41% from the latest price.
Stock Forecasts
2 weeks ago · businesswire.com
Tempus to Present at the 24th Annual Needham Virtual Healthcare ConferenceCHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will present at the 24th Annual Needham Virtual...
